摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

methyl 3-(2,2-dibromoacetyl)benzoate | 373648-98-7

中文名称
——
中文别名
——
英文名称
methyl 3-(2,2-dibromoacetyl)benzoate
英文别名
3-(2,2-Dibromo-acetyl)-benzoic acid methyl ester;Methyl 3-(2,2-dibromoacetyl)benzoate
methyl 3-(2,2-dibromoacetyl)benzoate化学式
CAS
373648-98-7
化学式
C10H8Br2O3
mdl
——
分子量
335.98
InChiKey
DVXDEXLEBZYZJR-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    3.6
  • 重原子数:
    15
  • 可旋转键数:
    4
  • 环数:
    1.0
  • sp3杂化的碳原子比例:
    0.2
  • 拓扑面积:
    43.4
  • 氢给体数:
    0
  • 氢受体数:
    3

上下游信息

  • 上游原料
    中文名称 英文名称 CAS号 化学式 分子量

反应信息

  • 作为反应物:
    描述:
    methyl 3-(2,2-dibromoacetyl)benzoate二甲基亚砜 为溶剂, 反应 24.0h, 生成 methyl 3-(6-chloro-7-iodo-3-oxo-3,4-dihydroquinoxalin-2-yl)benzoate
    参考文献:
    名称:
    一种具有AMPK激动活性的化合物及其前药的制备和应用
    摘要:
    本发明涉及一种具有AMPK激动活性的化合物及其前药,以及所述化合物及其前药的制备方法和医药用途。本发明所述化合物具有式(Ⅰ)所示结构,所述化合物的前药具有式(Ⅱ)所示结构,其中各基团和取代基如说明书中所定义。本发明公开了所述化合物的制备方法及其在预防和治疗AMPK相关疾病中的用途,所述AMPK相关的疾病包括但不限于能量代谢异常相关疾病、神经退行性疾病和炎症相关疾病等。
    公开号:
    CN113549010A
  • 作为产物:
    描述:
    3-乙酰基苯甲酸甲酯 作用下, 以 氯仿 为溶剂, 以3.73 g (73%)的产率得到methyl 3-(2,2-dibromoacetyl)benzoate
    参考文献:
    名称:
    Gastrin and cholecystokinin receptor ligands(II)
    摘要:
    取代咪唑(1)可作为血管紧张素II受体拮抗剂。这些化合物具有治疗高血压和充血性心力衰竭的活性。还描述了含有新型咪唑的药物组合物和使用它们的药物方法,单独或与其他药物一起使用,特别是利尿剂和非甾体抗炎药(NSAID)。
    公开号:
    US20030199565A1
点击查看最新优质反应信息

文献信息

  • US6878734B2
    申请人:——
    公开号:US6878734B2
    公开(公告)日:2005-04-12
  • [EN] GASTRIN AND CHOLECYSTOKININ RECEPTOR LIGANDS (II)<br/>[FR] LIGANDS (II) DE RECEPTEUR DE LA GASTRINE ET DE LA CHOLECYSTOKININE
    申请人:BLACK JAMES FOUNDATION
    公开号:WO2001085723A1
    公开(公告)日:2001-11-15
    Compounds of formula (I) and their pharmaceutically acceptable salts are ligands at gastrin and/or cholecystokinin receptors. X and Y are independently =N-, -N(R5)- (R5 being selected from H, Me, Et, Pr, Bn, -OH and -CH¿2COOR?6, wherein R6 represents H, Me, Et, Pr or Bn), =CH-, -S-, or -O-; R1 is H or C¿1?-C15 hydrocarbyl wherein up to three C atoms may optionally be replaced by N, O and/or S atoms, and up to three H atoms may optionally be replaced by halogen atoms; R?2¿ is selected from H, Me, Et, Pr and OH, each R2 being independently selected from H, Me, Et, Pr and OH when n is greater than 1; R3 (when n is 1) is selected from H, Me, Et and Pr; or (when n is greater than 1) each R3 is independently selected from H, Me, Et and Pr, or two R3 groups on neighbouring carbon atoms are linked to form a C¿3? to C6 carbocyclic ring, or two R?3¿ groups are absent from neighbouring carbon atoms which are linked by a double bond; or R?2 and R3¿ on the same carbon atom together represent an =O group; R4 is H or C¿1?-C15 hydrocarbyl wherein up to three C atoms may optionally be replaced by N, O and/or S atoms, and up to three H atoms may optionally be replaced by halogen atoms; Z is a diradical derived from an optionally substituted aromatic or non-aromatic C5 or C6 carbocycle, wherein 1, 2 or 3 C atoms are optionally replaced by N, O and/or S; Q is a 6-membered aromatic carbocycle (optionally substituted with 1 or 2 V groups and/or 1, 2 or 3 T groups) wherein 1, 2 or 3 C atoms are optionally replaced by N; V is -CO-NH-SO2-Ph, -SO2-NH-CO-Ph, -CH2OH, or a group of the formula -R?7¿U, (wherein U is -COOH, tetrazolyl, -CONHOH or -SO¿3?H; and R?7¿ is a bond; C¿1? to C6 hydrocarbylene, optionally substituted by hydroxy, amino or acetamido; -O-(C1 to C3 alkylene)-; -SO2NR?8-CHR9¿-; -CO-NR?8-CHR9-, R8 and R9¿ being independently selected from H and methyl; or -NH-(CO)¿c?-CH2-, c being 0 or 1); T is C1 to C6 hydrocarbyl, -NR?10R11¿ (wherein R?10 and R11¿ are independently selected from H, Me, Et, Pr or Bn), -OMe, -OH, -CH¿2?OH, halogen or trihalomethyl. Compositions comprising a compound of formula (I) are also described.
查看更多